Osteoporosis is characterized by a reduction in bone PMO and it was suggested that isoflavones in soy might be density and strength to the extent that fractures occur after responsible for their protective effects on bone. [7] [8] [9] Of all the minimal trauma. It is well known that estrogen deficiency as in isoflavones, genistein has received the most attention. [10] postmenopause and ovariectomy leads to acceleration of bone Genistein (4',5,7-trihydroxyisoflavone) (1) is a major isoflavone resorption and rapid bone loss, resulting in the development phytochemical in some plants belonging to the leguminosae of osteoporosis. [1] family. It is known as a phytoestrogen that is capable of binding Current therapies recommended for postmenopausal osteoporosis (PMO) treatment include supplementation with estrogen or hormone replacement therapies (ERT or HRT). Estrogen is the most potent inhibitor of bone resorption and the most widely recommended therapy to reduce the rate of postmenopausal bone loss. However, available evidence appears to suggest that the long-term use of ERT has numerous side effects. [2, 3] Currently, natural alternatives with estrogen-like activities such as soy isoflavones are being investigated as possible alternatives for HRT. [4] [5] [6] Isoflavones are compounds in plant foods, particularly soybeans, which are structurally and functionally similar to estrogens. They have recently received considerable attention for their potential use in the prevention of postmenopausal bone loss. Data from animal experiments provided evidence that soy protein can attenuate to the estrogen receptor. [11] Much attention has been focused on the role of genistein in preventing bone loss resulting at least in part from estrogen deficiency. [12] [13] [14] Furthermore, the findings that genistein acts as a selective estrogen receptor modulator (SERM) on osteoblastic cells [15] and in ovariectomized (OVX) mice [16] highlights the possibility that this isoflavone phytochemical hardly affects the uterus in the dose ranges in which it exerts estrogen-like regulatory action on bone and bone marrow metabolism. However, some studies reported no overall association between genistein intake and BMD and fracture rates. The effect of genistein on bone loss is still a controversial subject.
The purpose of this study was to determine whether the administration of genistein is capable of preventing rapid in vivo and in vitro bone loss. Cell proliferation as well as the expression of some biochemical parameters of osteoblastic phenotypes were monitored. The in vivo effects of genistein on BMD and bone minerals including calcium and phosphorous were also evaluated.
Materials and Methods

Chemicals and animals
All drugs were prepared in dimethylsulfoxide (DMSO) and then diluted with the medium (final DMSO concentration ≤ 0.05% (v/v)). All other reagents were from Sigma Chemical Co. (St. Louis, MO, USA) unless otherwise stated. All chemicals Cambridge, MA). After 8 h, the medium was replaced with phenol red-free media containing 5% charcoal-dextran-treated FBS (CD-FBS) supplemented with different concentrations of genistein (10 -9 -10 -5 M). After 72 h of culture, cell proliferation was measured by the MTT assay. [17] This assay is based on the ability of viable cells to convert soluble 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) into an insoluble dark blue formazan reaction product. DMSO was then added and mixed thoroughly to dissolve the dark blue crystals. The plates were read by a microplate reader at a wavelength of 490 nm. were of analytical grade. Each experiment was repeated three
Alkaline phosphatase (ALP) activity ALP activity is a phenotypic marker for the early and mature Forty nine-week old mature female Sprague Dawley differentiation stages of osteoblast cells. After the cells were rats (obtained from the laboratory animal center of FMMU, cultured at a density of 9 × 10 4 cells/well into culture dishes Xi'an China; weighing in average: 223 ± 5.6 g) were housed for 12 h, the medium was replaced with phenol red-free DMEM four to a cage under standard laboratory conditions with containing 5% CD-FBS supplemented with 10 -6 M genistein. temperature ranging between 20 and 25ºC, relative humidity On days 3, 5 and 7, the medium was removed and the cell between 55-65% and a 12 h light / dark cycle (lights on monolayer was gently washed twice with PBS. The cells were 08:00). All rats were allowed free access to water and a lysed with 0.2% Triton X-100 and the lysate was centrifuged at pelleted commercial diet (containing 0.97% calcium, 0.85% 1 × 10 4 rpm for 5 min at 4°C. The clear supernatant was used phosphorus and 1.05 IU/g of Vitamin D3). After a week of for the colorimetric measurement of ALP activity and protein acclimation, animals were used for studies. The experimental concentration with an ALP kit (Sigma, St. Louis, MO, USA) protocol was approved by the Ethical Committee for Animal according to the manufacturer's instructions. ALP activity was Care of the Fourth Military Medical University. Efforts were normalized with the total protein content determined by using made to minimize animal suffering and to reduce the number the Bradford protein assay with bovine serum albumin (BSA) of animals used.
as a standard.
[18]
Rats were randomly allocated to six groups (n=8 each Measurement of BMD group). (6*8=48, earlier you said 32 animals were taken. If
Femurs and tibias were removed at the time of necropsy, sham=1 group, OVX=2 nd group getting vehical, groups 3, 4, 5 cleaned of soft tissue and stored at -70ºC until analysis. BMD get 4.5, 9 or 18 mg/kg genistein. After a week of recovery from analyses were performed on left legs (femur and tibia) by dual the operation, Sham-operated (SH group) and one OVX group energy X-ray absorptiometry (DEXA) (DPX-IQ 7040, Lunar Corp, (two groups) received vehical (1% DMSO water solutions). The USA) with small animal software 1.0. The results are expressed remaining three OVX groups were given genistein (4.5, 9 or 18 as mean ± SE (standard error). mg/kg/day respectively). All rats were given both vehicle and genistein by the intragastric route. After 12 weeks of treatment, Bone calcium, phosphorus content the animals were anesthetized beforehand by intraperitoneal The bone tissues were dried at 120°C for 12 h, weighed, then dissolved in 5% nitric acid solution. [19] Calcium and injection of sodium pentobarbital (45 mg/kg).
Phosphorus levels were determined by atomic absorption spectrophotometry (Solaar M6, Thermo Electron, USA), the MC3T3-E1 cells (RCB1126, an osteoblast-like cell line content was expressed as millimole per gram of dry bone. from C57BL/6 mouse calvaria) were purchased from the
Statistical analysis American Type Culture Collection (ATCC). Cells were cultured
The results were expressed as the mean ± SE. All data times.
Cell cultures
at 37°C in 5% CO 2 atmosphere in Dulbecco's Modified Eagle Medium (DMEM), high glucose (Gibco, invitrogen Corp.). Unless otherwise specified, the medium contained 10% heatinactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. During subculture, the medium was replaced every three days.
MTT assay
Cells were suspended in medium and plated at a density of 3.0 × 10 4 cells/well into a 96-well culture dish (Costar,
HO O OH O OH
was analyzed using one-way analysis of variance (ANOVA) followed by LSD t-test using SPSS statistical software (SPSS, Inc, Chicago, IL).
Results
Cell proliferation assay
The proliferation of osteoblast was evaluated using the MTT assay. Compared to the blank, cell numbers significantly increased by 28.1% (P < 0.05) due to treatment with 10 -6 M genistein, which was higher than other concentrations of genistein [ Figure 1 ].
ALP activity
ALP activity was measured to study the effect of genistein on osteoblast differentiation. Our experimental results showed that ALP activity rose significantly (105.1% vs control, P < 0.05) 
Wang, et al.: Effects of genistein in ostroporosis Conclusion
The present study demonstrates that genistein, an abundant soybean isoflavone, may prevent both in vivo and in vitro bone loss. Osteoblasts are the key cells involved in bone matrix (%) after 10 -6 M genistein was administered for five days. However, ALP activity reached the highest level (124.6% vs control, P < 0.01) after seven days [ Figure 2 ].
Bone mineral density (BMD)
The effect of 12 weeks of treatment on femoral and tibial BMD is illustrated in Figure 3 . Femoral and tibial BMDs were 22.7% and 17.0% lower in OVX rats than in intact controls (P < 0.01), while the BMDs in rats of the genistein groups (4.5, 9 and 18 mg/kg) were all significantly elevated and were 93.9, 103.1 and 100.6% of the SH group respectively.
Bone calcium, phosphorus content
Bone calcium and phosphorus contentwere found to decrease with ovariectomy (90.9 and 86.8% of the SH group). After 12 weeks of treatment with genistein, bone calcium levels were 96.3, 99.3 and 99.0% of the SH group and bone phosphorus levels were 98.8, 96.9 and 95.1% of the SH group. The effect of genistein at its mid-and high doses on bone calcium levels was especially significant (P < 0.05) as compared to that of the low dose [ Figures 4, 5] . 0% of SH group. The effect of genistein at middle (9 mg/kg) and high (18 mg/kg) doses on bone calcium was vs control, **P < 0.01). Data is expressed as the mean ±SE.
especially signi›cant (P < 0.05 vs low dose group). Data is expressed as the mean ± SE. *P < 0.05,**P < 0.01 vs OVX. Bone phosphorus content changes. OVX also reduced bone phosphorous, the effect being reversed by genistein treatment. After drug administration for 12 weeks, bone phosphorus was 98.8, 96.9 and 95.1% of SH group. Data is expressed as the mean SE. *P < 0.05 vs SH, **P < 0.01 vs SH. L: low dose (4.5 mg/kg), M: mid-dose (9 mg/kg), H: high dose (18 mg/kg).
